Citation Tools
PDFInflammatory bowel disease
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)